Clinical Trials Logo

Filter by:
NCT ID: NCT05112523 Recruiting - Bladder Cancer Clinical Trials

The Performance of Cancer Risk Genes in the Necessity of Secondary TURBT

RE-TURBT
Start date: December 20, 2020
Phase:
Study type: Observational

Investigators performed the Genetron Uro V1 test on the urine of patients before secondary TURBT and compared it with the final pathological results. To analyze the performance of the Genetron Uro V1 method in a study to predict the need for secondary TURBT in high-risk NMIBC patients and the correlation with patient's RFS and OS.

NCT ID: NCT05112211 Recruiting - Clinical trials for Thyroid Associated Ophthalmopathy

Multi-model Image of Doxycycline in TAO

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of doxycycline treating Thyroid Associated Ophthalmopathy by multi-modal image.

NCT ID: NCT05111860 Recruiting - Rectal Cancer Clinical Trials

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer

NCT ID: NCT05111626 Recruiting - Gastric Cancer Clinical Trials

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer

FORTITUDE-102
Start date: March 14, 2022
Phase: Phase 3
Study type: Interventional

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.

NCT ID: NCT05111366 Recruiting - Clinical trials for Hepatocellular Carcinoma

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

ALTER-H006
Start date: January 6, 2022
Phase: Phase 2
Study type: Interventional

This is An Open, Single Arm, Multicenter, Exploratory Phase II study, to evaluate the efficacy and safety of TQB2450 Plus anlotinib as adjuvant therapy in hepatocellular carcinoma(HCC) patients at high risk of recurrence after resection. The patients who are confirmed by Histology or cytology as HCC with high-risk recurrence after R0 liver resection will be enrolled. 18 cycles adjuvant treatment with TQB2450 Plus anlotinib can improve one-year recurrence free survival (RFS) rate of HCC patients after R0 surgical resection.

NCT ID: NCT05110807 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

Start date: January 5, 2022
Phase: Phase 1
Study type: Interventional

TQB3617 is a bromodomain and extra-terminal (BET) inhibitor that can competitively bind to bromodomains (BRDs) with Acetylated lysine(Kac) and block or partially block the role of KAc in subsequent gene transcription and regulation of chromatin structure, thereby playing an anti-tumor role.

NCT ID: NCT05110261 Recruiting - Clinical trials for Lower Respiratory Tract Infection

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

CHIMES
Start date: November 24, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China

NCT ID: NCT05110040 Recruiting - Clinical trials for Thyroid Associated Ophthalmopathy

Multi-model Image of Immunosuppressive Agents in TAO

Start date: October 15, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of immunosuppressive agents treating Thyroid Associated Ophthalmopathy by multi-model image.

NCT ID: NCT05108909 Recruiting - Clinical trials for MTBI - Mild Traumatic Brain Injury

Rapid Diagnosis and Prognosis Recognition of Imaging and Biomarkers in Mild to Moderate Traumatic Brain Injury

Start date: September 1, 2021
Phase:
Study type: Observational

The investigators will carry out multi-center and large sample research based on the Chinese population, screen the optimal diagnostic and prognosis recognition biomarkers and analyze the diagnostic critical cutoff values in patients with mild to moderate traumatic brain injury, so as to provide a substantial basis for clinical diagnosis and prognosis recognition.

NCT ID: NCT05108779 Recruiting - Advanced Tumor Clinical Trials

QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors

Start date: November 9, 2021
Phase: Phase 1
Study type: Interventional

To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies.